Ivan Hyep, Chief Financial Officer at Bicara Therapeutics Inc. (BCAX), sold 60,770 shares at $18.22 ($1.1M) on 2025-10-07, disclosed to the SEC on 2025-10-08.
Scheduled sale ($1.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.17 | 6,514 | $118K | 10.7% |
| 2 | $18.17 | 6,514 | $118K | 10.7% |
| 3 | $18.22 | 18,244 | $332K | 30.0% |
| 4 | $18.22 | 18,244 | $332K | 30.0% |
| 5 | $18.21 | 5,627 | $102K | 9.3% |
| 6 | $18.21 | 5,627 |
| $102K |
| 9.3% |
| Total | $18.21 avg | 60,770 | $1.1M | 100% |
| Filing → |
| BCAX | SELL | 2026-05-26 | $188K | — | Filing → |
| BCAX | SELL | 2026-04-22 | $212K | — | Filing → |
| BCAX | SELL | 2026-03-24 | $341K | — | Filing → |